Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients

Complement C5 inhibitor eculizumab has a great impact on the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). However, this treatment success has a major drawback: a substantially increased susceptibility for life-threatening Neisseria meningitidis infections. Therefore, N menin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Langereis, Jeroen D., van den Broek, Bryan, Franssen, Sjoerd, Joosten, Irma, Blijlevens, Nicole M. A., de Jonge, Marien I., Langemeijer, Saskia
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7422103/
https://ncbi.nlm.nih.gov/pubmed/32766853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002497
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados